

Origin and Regimen of Diabetic Nephropathy

Nikhila Vengala*

Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Pune, Maharashtra, India

Review Article

Received: 10/12/2016

Revised: 15/12/2016

Accepted: 20/01/2017

*For Correspondence

Nikhila Vengala, M. Pharmacy,
Poona College of Pharmacy,
Bharati Vidyapeeth Deemed
University, Pune, Maharashtra,
India

E-mail:

nikhilavengala25@gmail.com

Keywords: Clinical trials, Diabetic Nephropathy, Treatment, Novel therapeutic agents.

ABSTRACT

[Diabetic nephropathy](#) remains the foremost common cause of end-stage nephritic disease worldwide. The present standard of medical care for diabetic kidney disease involves rigorous vital sign management via blockade of the renin-angiotensin system and control of hyperglycemia. Despite these methods, [diabetic kidney disease](#) continues to be seen to progress unrelentingly. A pressing would like for novel therapeutic agents have burning endless basic science research outcomes and clinical trials within the look for an additional specific medical care. Throughout the method, solely a couple of accessory agents have shown experimental promise and even fewer have incontestable effect in clinical trials. Treatment in diabetic nephropathy include glycemic management, treatment of hypertension, lipidemia, cease of smoking, protein restriction and [renal replacement therapy](#). Complex approach includes combined medical care targeting hyperglycemia, high blood pressure, microalbuminuria, and dyslipidemia.

INTRODUCTION

Diabetic nephropathy (DN) refers to a characteristic set of structural and practical excretory organ abnormalities in patients with polygenic disease. The structural abnormalities embody kidney hypertrophy, increase in glomerular basement membrane thickness, [nodular and diffuse glomerulosclerosis](#), tubular atrophy and interstitial fibrosis [1-5]. The practical alterations embody early increase in [glomerular filtration rate](#) with [intraglomerular hypertension](#), consequent proteinuria, systemic hypertension, and eventual loss of renal function^[6-12]. DN are often divided into 5 stages: 1) early hypertrophy stage characterized by increase in excretory organ plasma flow and GFR; 2) silent stage, that is related to delicate morphological changes, together with thickening of the capillary vessel basement membrane, capillary vessel hypertrophy, mesangial, and tubulointerstitial expansion; 3) early DN characterized by microalbuminuria with probably onset of hypertension; 4) open DN characterized by dipstick positive proteinuria; and 5) end-stage excretory organ sickness (ESRD) with azotemia^[13-22]. However, it's usually tough to document these varied stages during a diabetic patient in clinical observe due to contradictory factors, like vital sign medications, that modify the natural course of DN. The purpose of [Open access journals](#) is to spread information and permit that information to be designed upon. It has significant positive impact on everything from education to apply of medication to the flexibility of entrepreneurs to initiate. It provides access to everyone and so scholars globally can find and use research work with ease.

In order to promote awareness among the people, physicians and research experts unite to form a [society](#) or an organization. The main aim of these societies is to counsel and promote awareness among the victims of renal disorders as well as healthy personnel^[23-33]. Major societies like [European Biotechnology Thematic Network Association \(EBTNA\)](#) establish the industrial needs, to define course programed objectives, the course contents, the various professional profiles, to establish common criteria of evaluation, to favor the applicative use, the research and didactic integration and to promote continuous formation. [Diabetes Association of Malawi](#) provision of treatment and with the availability of appropriate drugs that the diabetic patients were experiencing. [Lithuanian society of Hypertension](#) promoting scientific research and knowledge to prevent heart diseases and stroke in hypertension and related cardiovascular diseases^[34-41].

Open Access literature plays a very important role in proving the information and current researches worldwide. [Journal of Nephrology & Therapeutics](#) includes fields related to Kidney diseases like glomerulonephritis, tubular diseases, electrolyte disturbances, and hypertension. It provides information related to therapeutic strategies like Dialysis, Hemofiltration, Diabetic Nephropathy, Renal Replacement Therapy, Transplantation etc. Conferences like

[9th International Conference on Nephrology & Therapeutics](#) held at **Orland, USA** dated on **September 29-30**, a keynote speech delivered by Michael F Michelis related to “New approaches to preventing progressive renal function”^[42-50]. [Journal of Diabetes & Metabolism](#) is an international [peer-reviewed scholarly journal](#), published research articles on Diabetic Nephropathy as a Special edition in its Volume 4, Issue S9. An abstract entitled “[Diabetic nephropathy- What is new?](#)” illustrated the several nephron-protective strategies in Diabetic Nephropathy^[51-68].

[Journal of Kidney](#) highlights on new discoveries majorly on the research going in the field of Clinical Nephrology. The open access journals on nephrology are the peer-reviewed journals that meet all the standards of the journal content, reviewer’s agreement and acceptance of respective editors in order to publish an article. These journals provides the unimpeded distribution of its content through online open access and thereby helps in improving the citations for authors and attaining good [journal impact factors](#) ^[69,70].

BURDEN OF DIABETIC NEPHROPATHY

The burden of diabetes mellitus is apace rising. Current projections estimate the world prevalence of diabetic people to rise from 6.4% (285 million) in 2010 to 7.7% (439 million) in 2030. The most drawbacks with this illness entity are its propensity to incur macro- and microvascular complications over time, disabling each the individual and our resource restricted aid system^[71-90].

Diabetic kidney disease (DN) is calculable to have an effect on tierce of people with DM and is related to significant vas morbidity and mortality. It’s the leading reason behind end-stage nephritic illness (ESRD) worldwide, accounting for forty second of all patients on [nephritic replacement medical aid](#) within the USA. The magnitude of this clinical entity continues to grow in association with associate degree increasing diabetic population and remarkably the surplus mortality risk of DM is associated virtually entirely with the presence of DN. Thus, the rummage around for therapeutic modalities to stem this inexorable tide remains a pressing matter. Though no cure is on the market at this time, treatment choices to stop or slow illness progression square measure out there^[91-115].

The relative mortality [risk of cardiovascular disorder](#) (CVD) in patients diagnosed with type 1 diabetes (type one DM) is calculable to be ten times over age-matched people while not polygenic disorder. Notably, nephritic sickness and younger age onset of polygenic disorder will doubtless lead to cardiovascular risk factors (CVRF), like [high blood pressure](#), lipaemia and poor glycemc management. Diabetic patients with nephritic sickness are at the best risk for presenting multiple CVRF, and therefore the progression and severity of nephritic sickness will increase all causes of mortality. The correction of azotemic and hyperglycemic setting, potential vessel risk factors, is achieved with synchronous pancreas-kidney transplant (SPKT). The SPKT may be a treatment possibility for patients with sort one polygenic disorder and ESRD^[116-122].

CURRENT APPROACH TO DIABETIC NEPHROPATHY

Available therapeutic choices directed at delaying the progression of DN embrace glucose (BG) management, Improved vital sign (BP) management, interruption of the RAAS exploitation Angiotensin-Converting Enzyme Inhibitors (ACEI) and/or Angiotensin Type-1 (AT1) Receptor Blockers (ARBs) together with dietary modification and steroid alcohol lowering agents^[123-138].

Lifestyle modification

Although these modifications area unit typically neglected, they’re vital elements of the management of DN. These modifications embrace exercise as tolerated, smoking stop, decrease in alcohol consumption, and weight reduction in [overweight patients](#).

Glucose level control

Older patients with DMT2 square measure a really heterogeneous cluster with multiple co-morbidities, [an enlarged risk of hypoglycaemia](#), and a larger susceptiblensness to adverse effects of symptom medicine, creating treatment of DMT2 during this population difficult. There’s AN enlarged risk of falling and lots of have a decline in their practical standing. Thus, hypoglycaemia could lead to AN enlarged risk of traumatic falls or exacerbation of co-morbid conditions. Therefore, distinguishing the optimum glucose target for the aged is crucial.

Blood pressure control

Approximately four-hundredth of patients with DMT2 at the age of 45 is hypertensive; the proportion will increase to 60% by the age of 65. [Renal hypertension](#) markedly accelerate the progression of DN. Normotensive patients with advanced DN show slower progression compared with hypertensive patients of all ages. Many

randomized controlled trials indicate that multiple medication agents, typically quite, area unit usually needed to realize optimum BP management^[139-142].

Protein Restriction

The role of [dietary protein restriction](#) in chronic excretory organ wellness is polemical but, restriction of protein (0.6 g of protein/kg weight per day) and phosphorus (500 mg to one g of phosphorus per day) was shown to cut back the decline in capillary filtration rate, lower pressure level, and stabilize excretory organ perform compared with the next intake of protein and phosphorus in a very irregular trial involving patients with type-I polygenic disorder and obvious nephritis^[143-158].

Renal Replacement Therapy

The [renal replacement modalities](#) on the market for patients with ESRD from polygenic disorder embody [serosa chemical analysis, dialysis](#), and renal transplantation. Numerous studies have shown similar survival in dialysis and serosa chemical analysis, although patients area unit additional doubtless to follow dialysis than with serosa chemical analysis. Both hemo and serosa chemical analysis limits social life, leisure, and sexual issues. Patients with polygenic disorder could manifest pathology symptoms at a comparatively less-advanced degree of nephropathy than their nondiabetic counterparts^[159-175].

CONCLUSION

The prevalence of diabetic nephropathy has rapidly increased in developing countries like USA. Strategies for the first identification and treatment of diabetic nephropathy have evolved supported new clinical trials. In need of a definitive cure, the social and economic burden of patients with diabetic nephropathy reaching ESRD is ready to cripple the tending system within the future. A complex approach targeting strict [management of glucose, lipids](#), and pressure and use of antihypertensives in proteinuric patients are desirable. Additionally, low-priced community-based programs to extend physical activity and avoid unhealthy fashion decisions ought to be inspired, since this can cause reduction within the incidence of polygenic disorder within the public. This evidence-based approaches place stress on individualizing best glycemic management, [BP management with RAAS-blockade](#) as first-line agents, and improvement of ancient vessel risk factors. Successful outcomes may be achieved with treatment that comes with the same multifarious interventions to slow the progression of diabetic nephritic malady and its associated complications.

REFERENCES

1. Jorge C, et al. Chronic Kidney Disease Awareness in the Population of Moderate and High Cardiovascular Risk. *J Nephrol Ther.* 2016; 6: 261.
2. Einollahi B, et al. Comparison in Pattern of Quality of Life in Different Regions. *J Nephrol Ther.* 2016; 6:266.
3. Fourtounas C and Dousdampanis P. Kidney, Pancreas and Islet Transplant Options for Patients with Diabetic Nephropathy. *J Diabetes Metab.* 2013; S9:001.
4. Neves MDF, et al. Prevalence of Cardiovascular Risk Factors on Different Phases of Diabetic Nephropathy in Comparison to Type 1 Diabetes Recipients who had Undergone Simultaneous Pancreas Kidney Transplant. *J Diabetes Metab.* 2013; S9:002.
5. Chen H, et al. Fetal Programming of Renal Development–Influence of Maternal Smoking. *J Diabetes Metab.* 2013; S9:003.
6. Sharma V and Sharma PL. Role of Different Molecular Pathways in the Development of Diabetes-Induced Nephropathy. *J Diabetes Metab.* 2013; S9:004.
7. Kojima N, et al. Comparison of the Development Diabetic Induced Renal Disease in Strains of Goto-Kakizaki Rats. *J Diabetes Metab.* 2013; S9:005.
8. Iqbal S and Alam A. Renal Disease in Diabetes Mellitus: Recent Studies and Potential Therapies. *J Diabetes Metab.* 2013; S9:006.
9. Panchapakesan U, et al. DPP4 Inhibition in Human Kidney Proximal Tubular Cells - Renoprotection in Diabetic Nephropathy? *J Diabetes Metab.* 2013;S9:007.
10. Higuchi C, et al. A Pregnant Patient with Brittle Type 1 Diabetes Successfully Managed by CSII Therapy with Insulin Aspart. *J Diabetes Metab.* 2010;1:104.
11. Parajuli S. Skin Cancer in Kidney Transplant Recipients: A Nephrologist's Perspective. *J Kidney.* 2015;1:e101.

12. Viswanathan P. Precincts of Glomerular Disease Markers. *J Kidney*. 2015;1:e103.
13. Niemczyk M, et al. Liver Cysts in Autosomal Dominant Polycystic Kidney Disease. *J Kidney*. 2015;1:i101.
14. EL-Arabey AA and Abd-Allah AR. Antidepressants as a New Approach for Protective Interventions of Cisplatin-Induced Nephrotoxicity. *J Kidney*. 2015;1:102.
15. Hussein AB and Elderwy A. Rare Radiolucent Hydroxyadenine Renal Stones in 4 Years Old Boy. *J Kidney*. 2015;1:103.
16. Woods SA, et al. A Case Report of Immunoglobulin A-dominant Acute Postinfectious Glomerulonephritis in a Patient with a Horseshoe Kidney. *J Kidney*. 2015;1:104.
17. Chen J and Harris RC. Interactions of EGFR and the Hippo Pathway in Diabetic Nephropathy. *J Kidney*. 2015;1:105.
18. de Waal D. Medical Nutrition Therapy delays Dialysis and Improves Biomarkers. *J Kidney*. 2015;1:106.
19. Lerman MJ, et al. Post Kidney Transplant Refractory Hypertension and Bilateral Native Nephrectomy. *J Kidney*. 2015;1:107.
20. Lajdova I and Spustova V. Calcium Transport across Plasma Membrane in Early Stages of Chronic Kidney Disease – Impact of Vitamin D3 Supplementation. *J Kidney*. 2015;1:108.
21. Nakabayashi K. Anti-Glomerular Basement Membrane Glomerulonephritis and Vasculitis: The Existence of Two Different Pathogenetic Mechanisms for the Formation of Crescentic Glomerulonephritis with or without Vasculitis and the Association with Antineutrophil Cytoplasmic Antibody. *J Kidney*. 2016;2:e104.
22. Kaushik M, et al. Tubulocystic Carcinoma of the Kidney: An Evolving Entity. *J Kidney*. 2016;2:e105.
23. Rottembourg J, et al. The Complete Study of the Switch from Iron-Sucrose Originator to Iron-Sucrose Similar and Vice Versa in Hemodialysis Patients. *J Kidney*. 2016;2:110.
24. Ong WM and Zargar H. Composite Outcome Measures in Nephron- Sparing Surgery. *J Kidney*. 2016;2:111.
25. Nakamura Y, et al. Factorial Analysis on Individual Variability of Tacrolimus Extended-Release Formulation Pharmacokinetics in the Early Period after Renal Transplantation-Factors for AUC/LAUC Decrease. *J Kidney*. 2016;2:112.
26. Shrum S, et al. Cold Storage Exacerbates Renal and Mitochondrial Dysfunction Following Transplantation. *J Kidney*. 2016;2:114.
27. Sankin A. Discovering Biomarkers within the Genomic Landscape of Renal Cell Carcinoma. *J Kidney*. 2016;2:115.
28. Ito C and Nagata D. Profound Connection between Chronic Kidney Disease and Both Colorectal Cancer and Renal Cell Carcinoma. *J Kidney*. 2016;2:118.
29. Rossetto A, et al. Kidney Transplanted Population and Risk for De Novo Tumors. Is it Possible to Improve the Outcome? Definition of a Personal Risk Score. *J Kidney*. 2016;2:119.
30. Faber DA, et al. Demographic Characteristics of Non-directed Altruistic Kidney Donors in the United States. *J Kidney*. 2016;2:121.
31. Kadiroğlu AK. A TNF-Alpha Receptor Antagonist Etanercept and its Role in The Treatment of Early Period of Sepsis. *J Kidney*. 2016;2:123.
32. Zeisberg EM and Zeisberg M. Inhibition of Fibrogenesis upon Hydralazine-induced DNA Demethylation. *J Kidney*. 2016;2:124.
33. Raman VK, et al. Renal Denervation: Back to the Future?. *J Kidney*. 2016;2:125.
34. Bello A, et al. Prenatal Development of Yankasa Sheep (*Ovis aries*) Kidney: A Histomorphometric Study. *J Kidney*. 2016;2:126.
35. Mishra NM and Lal V. Luminex Crossmatch as a Successful Algorithm for Post-Transplant Follow-up in Developing Nations-A Study of 169 Consecutive Samples. *J Kidney*. 2016;2:127.
36. Quintavalle C, et al. The Renal Guard System for the Prevention of Contrast-Induced Acute Kidney Injury. *J Kidney*. 2016;2:128.
37. Li X, et al. Effect of Administration Duration of Low Dose Methotrexate on Development of Acute Kidney Injury in Rats. *J Kidney*. 2016;2:130.
38. Anvesh Kompelli, et al. Nontraumatic Renal Arteriovenous Fistula. *J Kidney*. 2016;2:3.

39. Kane Y, et al. Relevance of the GeneXpert Test for the Diagnosis of TB in Chronic Hemodialysis Patients in Casamance, South of Senegal. *J Kidney*. 2016;2:133.
40. Atapour A, et al. Plasma Aldosterone Level in Metabolic Syndrome Patients Compared with Individuals without Metabolic Syndrome. A Survey on Iranian Population. *J Kidney*. 2016;2:134.
41. Ribeiro C, et al. Effects of Moderate Intensity Physical Training in Neonatal Alloxan- Administered Rats. *J Diabetes Metab*. 2010;1:107.
42. Anwar AM, et al. Left Ventricular Remodeling in Diabetic Patients with and without Hypertension. *J Diabetes Metab*. 2010;1:108.
43. Calle MC, et al. Low Plasma Hdl Cholesterol and Elevated C Reactive Protein further Increase Cardiovascular Disease Risk in Latinos with Type 2 Diabetes. *J Diabetes Metab*. 2010;1:109.
44. Taloyan M, et al. Differences in Cardiovascular Risk Factors in Swedes and Assyrians/Syrians with Type 2 Diabetes: Association with Lifestyle-Related Factors. *J Diabetes Metab*. 2010;1:110.
45. Joffe B, et al. Spectrum of Autoimmune Disorders in Type 1 Diabetes – A Cross-Sectional Clinical Audit. *J Diabetes Metab*. 2010;1:112.
46. Kozian DH, et al. A Novel Val286Ala Polymorphism in the NPXXY Motif of the Sphingosine-1-Phosphate Receptor S1PR2 Associates with the Incidence and Age of Onset of Diabetes. *J Diabetes Metab*. 2010;1:113.
47. He Z. Diagnosis and Treatment of Diabetic Nephropathy in Type 1 and Type 2 Diabetes Patients. *J Mol Biomark Diagn*. 2016;7:295.
48. El-Mousalamy AMD, et al. Aqueous and Methanolic Extracts of Palm Date Seeds and Fruits (*Phoenix dactylifera*) Protects against Diabetic Nephropathy in Type II Diabetic Rats. *Biochem Physiol*. 2016;5:205.
49. Wanyama FM, et al. Evaluation of High Density Lipoprotein Cholesterol as a Predictor of Diabetic Nephropathy in Type 1 Diabetic Patients. *Clin Med Biochemistry Open Access*. 2016;2:117.
50. Burlaka I. Beyond Proteinuria: Apoptosis and Vitamin D3 State in Children with Diabetic Nephropathy. *J Clin Exp Pathol*. 2016;6:266.
51. Chen J and Harris RC. Interactions of EGFR and the Hippo Pathway in Diabetic Nephropathy. *J Kidney*. 2015;1:105.
52. Nakhoul F, et al. The Non Mineral Axis Klotho-Vitamin D in Diabetic Nephropathy: Review. *J Diabetes Metab*. 2015;6: 563.
53. Saxena A. Nutritional Approach to Diabetic Nephropathy. *Anat Physiol*. 2015;5:181.
54. Peres GB and Michelacci YM. The Role of Proximal Tubular Cells in the Early Stages of Diabetic Nephropathy. *J Diabetes Metab*. 2015;6:551.
55. Abdo S, et al. Reactive Oxygen Species and Nuclear Factor Erythroid 2-Related Factor 2 Activation in Diabetic Nephropathy: A Hidden Target. *J Diabetes Metab*. 2015;6:547.
56. Satoh M, et al. Combination Irbesartan/Amlodipine versus Irbesartan/Cilnidipine for Attenuation of Albuminuria in Rats with Streptozotocin-Induced Diabetic Nephropathy. *Pharm Anal Acta*. 2015;6:369.
57. Okafor UH, et al. Audit of Screening for Diabetic Nephropathy in a Teaching Hospital in Nigeria. *J Diabetes Metab*. 2015;6:525.
58. Balasubramanian T, et al. Effect of *Stereospermum suavelolens* on Diabetic Nephropathy. *Clin Exp Pharmacol*. 2014;4:162.
59. El hafez AA. Microinflammation as a Candidate for Diabetic Nephropathy. *Microinflammation*. 2014;1:101.
60. Bahri NS, et al. Type 2 Diabetes Mellitus and Hepatitis C are Unlikely Contributors in a Case of Progression of Diabetic Nephropathy to End Stage Renal Disease. *J Diabetes Metab*. 2014;5:349.
61. Kuricova K, et al. Association of the Arg72Pro Polymorphism in p53 with Progression of Diabetic Nephropathy in T2DM Subjects. *J Nephrol Ther*. 2014;4:153.
62. Saito-Hakoda A, et al. Is Heparan Sulfate in the Glomerular Basement Membrane Necessary for the Etiology of Diabetic Nephropathy? *J Biomol Res Ther*. 2014;3:e127.
63. Tkachenko O and Schrier RW. Blood Pressure Control in Diabetic Nephropathy. *J Nephrol Ther*. 2014;4:148.
64. Arora MK and Singh UK. Combination of PPAR- α Agonist and DPP-4 Inhibitor: A Novel Therapeutic Approach in the Management of Diabetic Nephropathy. *J Diabetes Metab*. 2013;4:320.

65. Sharifi F, et al. Effect of Raloxifen on Renal Function in Post-Menopausal Women with Diabetic Nephropathy: a Double Blind Clinical Trial. *J Nephrol Ther.* 2013;3:135.
66. Purkait P, et al. Analysis of Aldosterone Synthase Gene Promoter (- 344 C >T) Polymorphism in Indian Diabetic Nephropathy Patients. *J Diabetes Metab.* 2013;4:271.
67. Lee HS. Pathogenic Role of TGF- β in Diabetic Nephropathy. *J Diabetes Metab.* 2013;S9:008.
68. Panchapakesan U, et al. DPP4 Inhibition in Human Kidney Proximal Tubular Cells - Renoprotection in Diabetic Nephropathy? *J Diabetes Metab.* 2013;S9:007.
69. Fournounas C and Dousdampanis P. Kidney, Pancreas and Islet Transplant Options for Patients with Diabetic Nephropathy. *J Diabetes Metab.* 2013;S9:001.
70. Neves MDF, et al. Prevalence of Cardiovascular Risk Factors on Different Phases of Diabetic Nephropathy in Comparison to Type 1 Diabetes Recipients who had Undergone Simultaneous Pancreas Kidney Transplant. *J Diabetes Metab.* 2013;S9:002.
71. Abdel-Rahman EM, et al. Management of Diabetic Nephropathy in the Elderly: Special Considerations. *J Nephrol Therapeut.* 2012;2:124.
72. Velez MG and Bhalla V. The Role of the Immune System in the Pathogenesis of Diabetic Nephropathy. *J Nephrol Therapeutic.* 2012;S2:007.
73. Romero MJ and Caldwell RW. The proximal tubule in progressive diabetic nephropathy: Are tubular polyamines a new paradigm for developing therapies?. *J Autacoids.* 2012;1:e115.
74. Mizuiri S, et al. ACE2- Ang 1-7-MAS Axis in Human Diabetic Nephropathy. *J Nephrol Therapeutic.* 2012;S2:005.
75. Li F and Takahashi N. eNOS and Diabetic Nephropathy. *J Nephrol Therapeutic.* 2012;S2:004.
76. Jia Z, et al. Beneficial Effect of Rhein on the Treatment of Diabetic Nephropathy in Nonobese Diabetic (NOD) Mice. *J Nephrol Therapeutic.* 2012;2:112.
77. Soetikno V, et al. Role of Protein Kinase C-MAPK, Oxidative Stress and Inflammation Pathways in Diabetic Nephropathy. *J Nephrol Therapeutic.* 2012;S2:001.
78. Futrakul N and Futrakul P. Diabetic Nephropathy: Current Concept of Therapeutic Strategy Toward Self-Sufficiency. *J Nephrol Therapeutic.* 2011;S2:002.
79. Srinubabu G, et al. Quantitative Analysis of Cytokines in Diabetic Nephropathy. *J Proteomics Bioinform.* 2009;2:217-221.
80. Serigne G, et al. Dent disease: About 4 Adult Observations Monitored in the Department of Nephrology and Organ Transplantation of Toulouse, France. *J Clin Exp Nephrol.* 2016;1:17.
81. Kaltsatou A. The Impact of Inflammation on Cognitive Impairment in Chronic Kidney Disease patients. *J Clin Exp Nephrol.* 2016;1:20.
82. Kfoury H, et al. The Prognostic Significance of IgG4 Deposition in Membranous Nephropathy and Its Impact on the Therapeutic Regimen. *J Clin Exp Nephrol.* 2016;1:9.
83. Chan JCM. Children with Chronic Kidney Disease: A Closer Look at Calcium, Phosphate and Vascular Calcification. *J Clin Exp Nephrol.* 2016;1:10.
84. Buchanan PM, et al. The Clinical and Financial Burden of Early Dialysis After Deceased Donor Kidney Transplantation. *J Nephrol Therapeutic.* 2011;S4:001.
85. Graff RJ, et al. The Role of the Crossmatch in Kidney Transplantation: Past, Present and Future. *J Nephrol Therapeutic.* 2012;S4:002.
86. Ercole PM, et al. Costs and Outcomes of Privately-Insured Kidney Transplant Recipients by Body Mass Index. *J Nephrol Therapeutic.* 2012;S4:003.
87. Cogar SM, et al. Effect of Spironolactone on Chronic Allograft Nephropathy in Rats. *J Nephrol Therapeutic.* 2012;S4:004.
88. Moscarelli L, et al. BKV-DNA Replication in Renal Transplant Recipients: Early Discontinuation of Mycophenolate Mofetil or an Early Combination Therapy with Fluoroquinolones and Activated Vitamin D. What Is the Best Strategy for Management? *J Nephrol Therapeutic.* 2012;S4:005.
89. Gleisner AL, et al. Renal Dysfunction in Liver Transplant Candidates: Evaluation, Classification and Management in Contemporary Practice. *J Nephrol Therapeutic.* 2012;S4:006.
90. Waterman AD, et al. Transplant Education Practices and Attitudes in Dialysis Centers: Dialysis Leadership Weighs In. *J Nephrol Therapeutic.* 2012;S4:007.

91. Berardinelli L, et al. Living Donor Transplantation of Kidneys with Fibromuscular Dysplasia: Indications, Surgical Techniques and Long Term Results in 11 Cases. *J Nephrol Therapeutic*. 2012;S4:008.
92. Belaiche S, et al. Drug Interaction with Pristinamycin in a Kidney and Pancreas Transplant Patient. *J Nephrol Therapeutic*. 2012;S4:009.
93. Yamaguchi T, et al. Comparison of Overall Survival after Nephron-Sparing Surgery and Radical Nephrectomy on the Basis of Preoperative Renal Function and Tumor Size. *J Nephrol Ther*. 2016;6:258.
94. Yamaguchi T, et al. Categorized Preoperative Estimated Glomerular Filtration Rate as a Criterion for Choosing Between Radical or Partial Nephrectomy for Renal Tumor. *J Nephrol Ther*. 2016;6:259.
95. Mccay J and Louden J. A Retrospective Study into the Use of Prophylactic Antibiotics Pre-Central Venous Catheter Insertion and the Associated Patient Outcomes. *J Nephrol Ther*. 2016;6:260.
96. Jorge C, et al. Chronic Kidney Disease Awareness in the Population of Moderate and High Cardiovascular Risk. *J Nephrol Ther*. 2016;6:261.
97. Sahu N, et al. Unusual Case of New Onset Diabetes Mellitus Presenting with Diabetic Ketoacidosis and Cerebral Edema with Literature Review. *J Nephrol Ther*. 2016;6:262.
98. Zakharova EV, et al. Hypocomplementemic Urticarial Vasculitis with Crescentic Glomerulonephritis, Interstitial Nephritis and Small Vessel Vasculopathy: Case Report and Mini-Review. *J Nephrol Ther*. 2016;6:263.
99. Al-Nasser MS, et al. Therapeutic Drug Monitoring of Tacrolimus in Saudi Kidney Transplant Patients. *J Nephrol Ther*. 2016;6:264.
100. Salem NA and Salem EA. Hepatorenal and Testicular Protective Effects of Lycopene against Cadmium Induced Toxicity in Male Rats. *J Nephrol Ther*. 2016;6:265.
101. Einollahi B, et al. Comparison in Pattern of Quality of Life in Different Regions. *J Nephrol Ther*. 2016;6:266.
102. Oezcelik A, et al. Long Term Success of Kidney Transplantation after Triple Cold and Triple Warm Ischemic Time. *J Kidney*. 2016;2:132.
103. Kane Y, et al. Relevance of the GeneXpert Test for the Diagnosis of TB in Chronic Hemodialysis Patients in Casamance, South of Senegal. *J Kidney*. 2016;2:133.
104. Li X, et al. Effect of Administration Duration of Low Dose Methotrexate on Development of Acute Kidney Injury in Rats. *J Kidney*. 2016;2:130.
105. Raman VK, et al. Renal Denervation: Back to the Future?. *J Kidney*. 2016;2:125.
106. Bello A, et al. Prenatal Development of Yankasa Sheep (*Ovis aries*) Kidney: A Histomorphometric Study. *J Kidney*. 2016;2:126.
107. Mishra NM and Lal V. Luminex Crossmatch as a Successful Algorithm for Post-Transplant Follow-up in Developing Nations-A Study of 169 Consecutive Samples. *J Kidney*. 2016;2:127.
108. Quintavalle C, et al. The Renal Guard System for the Prevention of Contrast-Induced Acute Kidney Injury. *J Kidney*. 2016;2:128.
109. Faber DA, et al. Demographic Characteristics of Non-directed Altruistic Kidney Donors in the United States. *J Kidney*. 2016;2:121.
110. Weigand K, et al. Living Kidney Donation in Germany – A Topical Overview. *J Kidney*. 2016;2:117.
111. Youssefi N and Chobanian M. Bordetella Bronchiseptica in a Kidneypancreas Transplant Recipient after Dog Vaccination. *J Kidney*. 2016;2:120.
112. Shrum S, et al. Cold Storage Exacerbates Renal and Mitochondrial Dysfunction Following Transplantation. *J Kidney*. 2016;2:114.
113. Sankin A. Discovering Biomarkers within the Genomic Landscape of Renal Cell Carcinoma. *J Kidney*. 2016;2:115.
114. Nakamura Y, et al. Factorial Analysis on Individual Variability of Tacrolimus Extended-Release Formulation Pharmacokinetics in the Early Period after Renal Transplantation-Factors for AUC Decrease. *J Kidney*. 2016;2:112.
115. Lajdova I and Spustova V. Calcium Transport across Plasma Membrane in Early Stages of Chronic Kidney Disease – Impact of Vitamin D3 Supplementation. *J Kidney*. 2015;1:108.
116. de Waal D. Medical Nutrition Therapy delays Dialysis and Improves Biomarkers. *J Kidney*. 2015;1:106.

117. Lerman MJ, et al. Post Kidney Transplant Refractory Hypertension and Bilateral Native Nephrectomy. *J Kidney*. 2015;1:107.
118. Chen J and Harris RC. Interactions of EGFR and the Hippo Pathway in Diabetic Nephropathy. *J Kidney*. 2015;1:105.
119. Woods SA, et al. A Case Report of Immunoglobulin A-dominant Acute Postinfectious Glomerulonephritis in a Patient with a Horseshoe Kidney. *J Kidney*. 2015;1:104.
120. EL-Arabey AA and Abd-Allah AR. Antidepressants as a New Approach for Protective Interventions of Cisplatin-Induced Nephrotoxicity. *J Kidney*. 2015;1:102.
121. Niemczyk M, et al. Liver Cysts in Autosomal Dominant Polycystic Kidney Disease. *J Kidney*. 2015;1:i101.
122. Parajuli S. Skin Cancer in Kidney Transplant Recipients: A Nephrologist's Perspective. *J Kidney*. 2015;1:e101.
123. Agarwal DK, et al. Impact of Renal Transplantation on Psychosocial Status of Human Immuno Deficiency Virus (HIV) Positive Patients. *J AIDS Clin Res*. 2016;7:554.
124. Alalawi F, et al. Liver Abscess; Uncommon Complication Following Renal Transplantation: Case Report with Review of Literatures . *J Transplant Technol Res*. 2016;6:159.
125. Lerman MJ and Aronoff R. Severe Hypocalcemia Following Spontaneous Abortion in a Renal Transplant Patient. *Med Rep Case Stud*. 2016;1:115.
126. Shoker A, et al. Differential Association Between Responder's HLA-DR Phenotypes and HLA-DR Antibody Production in Patients Awaiting for Renal Transplantation; Analysis of UNOS Database. *J Clin Exp Transplant*. 2016;1:103.
127. Amesty MV, et al. Adult-sized Renal Transplantation in Small Pediatric Recipients Achieves Long-term Outcomes Comparable to Size-matched Transplantation. *J Clin Exp Transplant*. 2016;1:105.
128. Galletta D, et al. The Complexity of Life Donor Renal Transplantation: The Role and Effectiveness of Multidisciplinary Approach in the Medical Route and Psychological Operation. *J Clin Res Bioeth*. 2016;7:289.
129. Shu-Ming Ji, et al. Clinical and Pathological Study of Polyomavirus-Associated Nephropathy after Renal Transplantation. *J Transplant Technol Res*. 2014;4:132.
130. Cavayero C and Kar PM. Overview of Renal Transplantation in the United States. *J Transplant Technol Res*. 2014;4:e131.
131. Trivedi H, et al. Regulatory T-Cells Support Stem Cell Therapy in Safe Minimization of Immunosuppression in Living Donor Renal Transplantation. *J Stem Cell Res Ther*. 2014;4:240.
132. Narayan, et al. Endovascular Repair of Late Onset Anastomosis Site Pseudoaneurysms Complicating Renal Transplantation. *J Vasc Med Surg*. 2014;2:156.
133. Kennard A, et al. BK Polyomavirus in Renal Transplantation. *Gen Med (Los Angel)*. 2015;3:154.
134. Nagib AM, et al. New Onset Diabetes Mellitus after Living Donor Renal Transplantation: A Unique Pattern in the Egyptian Population. *J Diabetes Metab*. 2015;6:519.
135. Lau KK and Butani L. Steroid Minimization in Pediatric Renal Transplantation. *J Nephrol Therapeutic*. 2012;2:e105.
136. Mohsin R, et al. Renal Transplantation in Patients with Lower Urinary Tract Dysfunction: A Single Center Experience from a Developing Country. *J Transplant Technol Res*. 2012;2:115.
137. Reinders MEJ and Hoogduijn MJ. NK Cells and MSCs: Possible Implications for MSC Therapy in Renal Transplantation. *J Stem Cell Res Ther*. 2014;4:166.
138. Shrestha BM. Immunology for Renal Transplantation: A Review. *J Transplant Technol Res*. 2014;4:130.
139. Hideaki I. Is Evidence-Based-Medicine Always the Gold Standard in Geriatric Nephrology? *Evidence Based Medicine and Practice*. 2016;1:105.
140. Anvesh Kompelli, et al. Nontraumatic Renal Arteriovenous Fistula. *J Kidney*. 2016;2:3.
141. Sarasamma S, et al. Pharmacogenomics of CYP3A5 Polymorphism: Predicting Doseadjusted Trough Levels of Tacrolimus in South Indian Renal Transplant Patients. *J Pharmacogenomics Pharmacoproteomics*. 2016;7:161.
142. Pathan AM, et al. Lumbar Artery Embolization for Control of Bleeding after Percutaneous Renal Biopsy. *Med Surg Urol*. 2016;5:159.

143. Galle J. Continuous Erythropoietin Receptor Activator (C.E.R.A.) Treatment of Renal Anemia in Patients with Chronic Kidney Disease: A Two-Year Observational Study. *J Nephrol Ther.* 2015;6:228.
144. Greydanus DE, et al. A Short Historic View of Nephrology upto the 20th Century . *Clinics Mother Child Health.* 2015;12:195.
145. Nagib AM, et al. New Onset Diabetes Mellitus after Living Donor Renal Transplantation: A Unique Pattern in the Egyptian Population. *J Diabetes Metab.* 2015;6:519.
146. Garcia-Garcia G and Jha V. CKD in Disadvantaged Populations. *Intern Med.* 2015;5:182.
147. Shivendra S, et al. Echocardiographic Changes in Patients with ESRD on Maintenance Hemodialysis-A Single Centre Study. *J Cardiovasc Dis Diagn.* 2014;2:165.
148. Cisse MM, et al. Light Chain Deposition Disease in Black African, Report of Three Cases from Senegal. *J Nephrol Therapeutic.* 2013;S1:003.
149. Cisse MM, et al. Obstetric Cortical Renal Necrosis, Even Reality in the Tropics. *J Nephrol Ther.* 2014;4:156.
150. Cisse MM, et al. Light Chain Deposition Disease in Black African, Report of Three Cases from Senegal. *J Nephrol Therapeutic.* 2013;S1: 003.
151. Sikaneta T, et al. Cardiopulmonary Resuscitation Success Rates in 402 Patients with and without Renal Impairment at Canada's Largest Community Hospital. *J Nephrol Ther.* 2013;3:136.
152. Zitman-Gal T, et al. Vitamin D and Vascular Smooth Muscle Cells: Gene Modulation Following Exposure to a Diabetic-Like Environment. *J Diabetes Metab.* 2012;3:218.
153. Burnier M, et al. Usefulness of Telemetric Blood Pressure Monitoring in Hypertensive Patients with Chronic Kidney Diseases. *J Nephrol Therapeut.* 2012;2:122.
154. Del Giudice A, et al. Increasing Incidence of Primary Aldosteronism in Patients Investigated for Resistant Hypertension: An Observational Study from a Nephrology Unit. *J Nephrol Therapeutic.* 2012;S3:007.
155. Hur E. Insight to Case Reports. *J Clinic Case Reports.* 2011;1:e104.
156. Checherita IA. Emergencies in Nephrology - Renal Dysfunction a Sufficient Mortality Predictor? *Emerg Med (Los Angel).* 2011;1:e102.
157. Menezes AM, et al. Mild Decrease in Renal Function in HIV-Infected Patients on Antiretroviral Therapy:A Neglected Diagnosis. *J AIDS Clin Res.* 2015;6:501.
158. McCullough PA, et al. Cardiorenal Syndromes: Advances in Determining Diagnosis, Prognosis, and Therapy. *J Cardiovasc Dis Diagn.* 2015;3:221.
159. Sultan S, et al. Endovascular Repair of a Type III Renal Artery Aneurysm using the Multilayer Flow Modulator: A Clinical Case Report. *J Vasc Med Surg.* 2015;3:216.
160. Qingwen L, et al. Diagnosis and Treatment of Abnormally Calcified Renal Masses (3 Case Reports). *J Health Edu Res Dev.* 2015;3:131.
161. Hanafy MS, et al. Evaluating the Efficacy of Bone Tracer 99mTC-MDP in Detecting Individual Renal Function Compared to Renal Cortical Imaging Agent 99mTC-DMSA. *J Nucl Med Radiat Ther.* 2015;S8: S8-003.
162. Ibegbulem CO, et al. Functional Assessments and Histopathology of Hepatic and Renal Tissues of Wistar Rats Fed with Cocoa Containing Diets. *J Nutr Food Sci.* 2015;S11:002.
163. Babu CSR, et al. Renal Fusion Anomalies: A Review of Surgical Anatomy. *Anat Physiol.* 2015;S5:001.
164. Pesce A and Puleo S. A Rare Case of Herniated Renal Cyst Through Grynfeltt's Triangle. *J Gastrointest Dig Syst.* 2015;5:304.
165. Darabont RO, et al. Renal Artery Stenosis and Acute Pulmonary Edema-A Possible Correlation beyond Pickering Syndrome. *J Clin Exp Cardiol.* 2015;6:377.
166. Amvosieva TV, et al. Viral Infections in Renal Transplant Recipients in Belarus. *J Infect Dis Ther.* 2015;3: 212.
167. Basu RK, et al. Assessment of Worldwide Acute Kidney Injury, Renal Angina and Epidemiology in Critically Ill Children (AWARE): A Prospective Study to Improve Diagnostic Precision . *J Clin Trials.* 2015;5:222.
168. Faruk EM, et al. Histological, Immunohistochemical and Biochemical Study on the Possible Cardioprotective and Antihypertensive Role of the Flavonoid in Unilateral Renal Artery Ligation of Adult Albino Rats. *J Cytol Histol.* 2015;6: 326.

169. Ahmed KM, et al. Oral and Dental Findings in Patients with End Stage Renal Disease Undergoing Maintenance Hemodialysis in Sulaimani City. *J Interdiscipl Med Dent Sci*. 2015;3:182.
170. Ahmed B, et al. Urinary Excretion and Renal Clearance of Allopurinol in Female Gout Patients. *J Anal Bioanal Tech*. 2015;6:243.
171. C Gan, et al. Haematological Problems and their Solutions in ABO-Incompatible Renal Transplants . *Biol syst Open Access*. 2015;4:133.
172. Faulkner J, et al. Inhibition of 12/15-Lipoxygenase Reduces Renal Inflammation and Injury in Streptozotocin-Induced Diabetic Mice. *J Diabetes Metab*. 2015;6:555.
173. Certík B, et al. Flank Incision Laparotomy Approach for Repair of Traumatic Left Renal Artery Thrombosis, Small Bowel and Transverse Colon Injury. *J Vasc Med Surg*. 2015;3: 201.
174. Nazar CMJ, et al. Role of Diabetes and Blood Pressure in the Advancement of Renal Disease. *Endocrinol Metab Synd*. 2015;4:176.
175. Parashari UC, et al. A Rare Case of Renal Cell Carcinoma in Left Renal Ectopia with Cervical Spine Metastasis Presented as Quadriplegia. *Med Surg Urol*. 2015;4:149.